Louis Edward Tamayo - 29 Aug 2025 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Financial Officer
Signature
/s/ Youjin Choi, Attorney-in-Fact
Issuer symbol
LXEO
Transactions as of
29 Aug 2025
Net transactions value
$0
Form type
4
Filing time
03 Sep 2025, 14:00:05 UTC
Previous filing
27 Aug 2025
Next filing
06 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Tamayo Louis Edward Chief Financial Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK /s/ Youjin Choi, Attorney-in-Fact 03 Sep 2025 0002083206

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Award $0 +45,000 $0.000000 45,000 29 Aug 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXEO Stock Option (right to buy) Award $0 +280,000 $0.000000 280,000 29 Aug 2025 Common Stock 280,000 $4.79 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on August 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
F2 The reported securities are RSUs.
F3 25% of the shares underlying the option vest and become exercisable on August 15, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.